[MOL] New Product fot the Diagnosis and Risk of Blood Clotting Disorders [02740] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] New Product fot the Diagnosis and Risk of Blood Clotting Disorders



Good MOrning My FRiends,

Thought this might be of interest. One of the secondary conditions to,
say lymphatic involvement malignancy is the impeding flow of blood to
the major organs. My wife experienced this at the time of diagnosis 5
years ago and it has been a major concern to this day. The condition is
called superior vena cava syndrome or thrombosis of the neck, impedment
blood flow from a major vein to the heart as teh lymph nodes were
enlarged impeding blood flow. The following data provdies some hope to
those that may be concerned with this condition. 


Corgenix Receives FDA Clearance to Market Four New Products for the
Diagnosis
and Risk Assessment of Blood Clotting Disorders

DENVER, Jan. 5 /PRNewswire/ -- Corgenix Medical Corporation (OTC
Bulletin
Board: COGX) announced today that it has received clearance to market
four new
products for the diagnosis and risk assessment of blood clotting
disorders
(thrombosis) from the US Food and Drug Administration (FDA).

Three of the new test kits cleared by the FDA detect antibodies to Beta
2
Glycoprotein I which are indicators of increased risk for developing
clinical
thrombosis (blood clots) as seen in patients with deep venous
thrombosis,
heart attacks and strokes.  These assays are more specific for
thrombosis and
represent a step forward in the diagnosis and management of blood
clotting
disease.

A fourth test kit (Monoclonal Free Protein S Antigen Test Kit) also
cleared by
the FDA measures Free Protein S which is an important physiological
regulator
of coagulation.  A deficiency of Protein S may lead to serious
thrombotic
(blood clot) events.  The use of a monoclonal antibody specific for Free
Protein S provides a more specific, rapid and convenient laboratory
test.

The American Thrombosis Association estimates between 5 to 20 million
cases of
blood clot-related diseases in the U.S. each year.  Approximately 1.7
million
Americans suffer heart attacks or strokes annually, resulting in 800,000
deaths.  The frequency of venous thrombosis in the general population
has been
estimated to be approximately 1 in 1,000 individuals per year.

Douglass T. Simpson, President of Corgenix said, "With the clearance
from the
FDA to market these coagulation assays, the company will immediately
offer
these test kits to clinical laboratories worldwide to continue building
a
leadership role in the growing vascular disease testing market."

Corgenix Medical Corporation is based in metropolitan Denver and is
focused on
the development and promotion of specialized diagnostic test kits for
vascular
diseases, immunological disorders, bone diseases and joint diseases. 
Corgenix
diagnostic products are commercialized for use in clinical laboratories
throughout the world.

Statements in this release that are not strictly historical are
"forward-
looking" statements within the meaning of the Private Securities
Litigation
Reform Act of 1995, and should be considered as subject to various risks
and
uncertainties that could cause actual results to differ materially from
those
anticipated.

For more information, contact Chris Wolfe, investor relations
coordinator of
Corgenix at (303) 457-4345 ext.147.

God Bless
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------